We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Percutaneous Mesh Device Treats Congenital Heart Defect

By HospiMedica International staff writers
Posted on 24 Jan 2019
Print article
Image: A pea-sized mesh device helps treat PDA (Photo courtesy of Abbott).
Image: A pea-sized mesh device helps treat PDA (Photo courtesy of Abbott).
A minimally invasive transcatheter implant the size of a pea closes patent ductus arteriosus (PDA) in premature infants.

The Abbott (Abbott Park, IL, USA) Amplatzer Piccolo Occluder is a self-expanding, nickel-titanium wire mesh device that is inserted through a small incision in the leg and guided into either the aortic or pulmonary artery via an anterograde (venous) or a retrograde (arterial) approach. Because the device can be deployed in a minimally invasive percutaneous procedure, many premature neonatal intensive care unit (NICU) babies can be weaned from artificial respirator support soon after implantation.

“Piccolo is a critical advancement in the standard of care for the most vulnerable of premature babies who may not be able to undergo surgery to repair their hearts,” said Michael Dale, vice president of Abbott's structural heart business. “Our mission is to develop life-changing technology to help people live better lives through improved health. This approval is another important step toward achieving our mission for the patients and physicians we serve.”

“We’ve never had anything like this, a device from a major medical manufacturer that was specifically designed with these tiny, really at risk, very fragile babies in mind,” said Evan Zahn, MD, director of the congenital heart program at Cedars-Sinai Smidt Heart Institute (Los Angeles, CA, USA). “We’re talking about babies the size of the typical water bottle we all drink out of. They are incredibly frail, fragile and at risk for terrible morbidity and mortality.”

PDA is a congenital disorder in the heart wherein a neonate's ductus arteriosus fails to close, remaining patent (open), thus allowing part of the oxygenated blood from the left heart to return to the lungs by flowing from the aorta to the pulmonary artery. Early symptoms are uncommon, but in the first year of life include increased work of breathing and poor weight gain. With age, the PDA may lead to congestive heart failure (CHF) if left uncorrected. Neonates without adverse symptoms may simply be monitored as outpatients, while symptomatic PDA can be treated with both surgical and non-surgical methods.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Digital Radiography Generator
meX+20BT lite

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.